Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.96 USD | +1.02% | -2.31% | -9.34% |
04-24 | Gain Therapeutics, Inc. Announces Positive Results from the Single Ascending Dose Part of the Phase 1 Clinical Trial of GT-02287 | CI |
04-08 | Gain Therapeutics Names Gene Mack as CFO | MT |
Business Summary
Number of employees: 31
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Therapeutics
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -60.62% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Australia, Switzerland and Spain
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -60.62% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Matthias Alder
CEO | Chief Executive Officer | 59 | 18/10/21 |
Eric Richman
BRD | Director/Board Member | 63 | 30/06/20 |
Comptroller/Controller/Auditor | 35 | 30/06/22 | |
Corporate Officer/Principal | - | - | |
Manolo Bellotto
PRN | Corporate Officer/Principal | 53 | 31/12/17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Dov Goldstein
BRD | Director/Board Member | 56 | 31/12/20 |
Eric Richman
BRD | Director/Board Member | 63 | 30/06/20 |
Matthias Alder
CEO | Chief Executive Officer | 59 | 18/10/21 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 31/12/20 |
Director/Board Member | 68 | 31/12/20 | |
Jeffrey Riley
BRD | Director/Board Member | 61 | 30/04/19 |
Khalid Islam
FOU | Founder | 67 | 31/12/16 |
Claude Nicaise
BRD | Director/Board Member | 71 | 31/12/20 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 18,051,979 | 15,383,745 ( 85.22 %) | 0 | 85.22 % |
Company contact information
Gain Therapeutics, Inc.
4800 Montgomery Lane Suite 220
20814, Bethesda
+
http://www.gaintherapeutics.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-9.34% | 53.43M | |
+25.69% | 47.9B | |
+46.90% | 41.42B | |
-3.46% | 40.7B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- GANX Stock
- Company Gain Therapeutics, Inc.